Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug
ARS-interacting multifunctional proteins 2 (AIMP2) is known to be a powerful tumour suppressor. However, the target AIMP2-DX2, AIMP2-lacking exon 2, is often detected in many cancer patients and cells. The predominant approach for targeting AIMP-DX2 has been attempted via small molecule mediated inh...
Saved in:
Main Authors: | BoRa Lee (Author), Dae Gyu Kim (Author), Aram Lee (Author), Young Mi Kim (Author), Lianji Cui (Author), Sunghoon Kim (Author), Inhee Choi (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
by: Chao Wang, et al.
Published: (2022) -
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
by: Mingxing Hu, et al.
Published: (2020) -
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
by: Yujeong Moon, et al.
Published: (2023) -
Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs
by: Qiaohua Qin, et al.
Published: (2022) -
A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
by: Robin Thomas Ulrich Haid, et al.
Published: (2023)